New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
09:02 EDTACTGAcacia reaches settlement with Mallinckrodt over Exalgo
Actavis announced that it has reached a settlement with Mallinckrodt on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Under terms of the settlement agreement, Mallinckrodt has granted Actavis a royalty-free license to U.S. patents relating to Exalgo to sell Actavis' 32 mg product starting on May 15, 2014. Other details of the settlement were not disclosed.
News For ACTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
06:02 EDTACTGAcacia Research enter into settlement and patent license with C.R. Bard
Subscribe for More Information
October 1, 2015
06:01 EDTACTGAcacia Research signs patent license agreement with Alcatel-Lucent USA
Acacia Research's (ACTG) Labyrinth Optical Technologies subsidiary has entered into a settlement and patent license agreement with Alcatel Lucent (ALU) USA. The agreement resolves litigation that was pending in the U.S. Court for the Central District of California.
September 25, 2015
06:01 EDTACTGAcacia Research enters into settlement agreement with Zimmer Biomet
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use